PinkDx is an early-stage company whose vision is to positively impact the health of women throughout their life journey. We focus on addressing the medical problems that women uniquely face by applying sophisticated scientific approaches to resolve them and provide answers that have an immediate, positive impact on their lives. Our first indication will focus on overcoming diagnostic challenges for women who present with general symptoms that could signal a gynecological cancer. Led by a team of diagnostics industry veterans, PinkDx is privately held, with funding from prominent biotechnology investors, including Catalio Capital Management, The Production Board, Mountain Group Partners, Byers Capital and Mayo Clinic.